Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
Company actively advancing lead ophthalmology drug candidate to first Investigational New Drug (IND) filingREDWOOD CITY, Calif., Sept. 19, 2024 (GLOBE...